Surgery, Gastroenterology and Oncology
Vol. 20, Nr. 3, September 2015
Predictive biomarkers for chemotherapies in pancreatic cancer
Augustin Catalin Dima, Alina Dima, Sever Calin Moldovan, Mircea Ciurea
REVIEW, September 2015
Article DOI: 10.21614/jtmr-20-3-46
Pancreatic cancer is associated with high rates of mortality especially due to advanced stages of diagnosis. Adjuvant chemotherapy role is thus essential in the attempt to downstage the tumoral grade. In cases of locally advanced tumors, this step could be followed by curative surgical resection.
Characterization of predictor biomarkers for adjuvant chemotherapy has drawn increasing interest in molecular biology research of pancreatic cancer. Personalized treatment is one of the solutions proposed for advancing towards a better outcome. In this paper we discuss available predictor biomarkers with focus upon gemcitabine and FOLFIRINOX (5-fluoro uracil (5-FU), irinotecan and oxaliplatin) chemotherapy regimens, present approaches in advanced pancreatic cancer. Many data are current available in relation with gemcitabine chemotherapy regimen, where biomarkers like ribonucleotide reductase large subunit (RRM1), human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (dCK), human antigen R (HuR), and secreted protein acidic rich in cysteine (SPARC) were proposed.
Regarding the response to FOLFIRINOX components, other markers such as thymidylate synthethase (TS), topoisomerase I, and excision repair cross-complementation 1 (ERCC1) or KRAS mutation status were also investigated.

Key words: pancreatic cancer, chemotherapy, response predictor, biomarker

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 778



Video Abstracts


Open Access Fee

Members of the IASGO will not pay open access fee. Non-members of IASGO will pay publishing fee of €150. Publishing fee, which will cover the DOI, plagiarism check, the editing work.


Journal Subscriptions

Current Issue

Dec 2020

Supplements

Instructions for authors
Online submission
Contact
Print ISSN: 2559 - 723X

ISSN-L: 2559 - 723X

ISSN online: 2601 - 1700

Surgery, Gastroenterology and Oncology is indexed in Scopus, CrossRef (DOI: 10.21614/sgo)



Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.